Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Real World Post-Marketing Surveillance Study Assessing the Safety and Efficacy of Teneligliptin in Japanese Patients with Type 2 Diabetes Mellitus (T2DM)

Trial Profile

A Real World Post-Marketing Surveillance Study Assessing the Safety and Efficacy of Teneligliptin in Japanese Patients with Type 2 Diabetes Mellitus (T2DM)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teneligliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RUBY
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 23 Dec 2019 Status changed from active, no longer recruiting to completed, according to results published in the Advances in Therapy Journal.
    • 23 Dec 2019 Results assessing the 3-year safety and efficacy of teneligliptin in this study, were published in the Advances in Therapy Journal.
    • 01 Jun 2018 Interim results (data cut off: 28 Jun, 2017; n=11,425) published in the Diabetes Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top